Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$96.80 USD

96.80
467,848

-0.91 (-0.93%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $96.80 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (58 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks News

Envision Healthcare Divests AMR Unit, Streamlines Business

Envision Healthcare (EVHC) divests its American Medical Response business to reduce leverage and focus on high-growth business.

    5 Growth Stocks in MedTech Set to Scale Higher in 2018

    The U.S. MedTech markets have been riding high with merger and acquisitions in focus.

      Here's Why You Should Add Amedisys (AMED) to Your Portfolio

      Amedisys (AMED) witnesses encouraging growth in Medicare and non-Medicare revenues at the Home Health and Hospice divisions in fourth-quarter 2017.

        Amedisys (AMED) Strong on Buyouts & Solid Personal Care Unit

        Amedisys (AMED) forges ahead with buyouts to boost capacity and geographical presence.

          Amedisys (AMED) Q4 Earnings Miss, Revenues Beat Estimates

          Amedisys (AMED) registers strong growth across all segments in Q4.

            Amedisys (AMED) Strong on Home Health, Margin Decline a Woe

            Amedisys' (AMED) acquisition of Tenet Healthcare's home health and hospice operations in Arizona might help the company deliver high-quality post-acute services in the key markets.

              Veeva Systems' Product Portfolio Strong, Competition Rife

              Veeva Systems (VEEV) rides on growing demand for cloud-based and vault applications. However, the company faces cutthroat competition in the niche space.

                Abaxis (ABAX) at a 52-Week High: What's Driving the Stock?

                Abaxis (ABAX) rides high on recently received approval from USDA.

                  Intuitive Surgical Gains on FDA Approvals, Competition Rife

                  Intuitive Surgical (ISRG) gains significantly on CE Mark approval for da Vinci X in Europe.

                    Intuitive Surgical (ISRG) Beats on Q4 Earnings & Revenues

                    Intuitive Surgical (ISRG) gains from revenue growth in Instrument & Accessories plus Services and Systems segments in Q4.

                      PerkinElmer (PKI) Beats on Q4 Earnings, Issues 2018 Guidance

                      Solid performance in Discovery & Analytical Solutions segment drives PerkinElmer (PKI) in Q4. A strong guidance for FY18 instills investor's optimism.

                        Abbott (ABT) Tops Q4 Earnings and Revenues, Issues Guidance

                        Abbott (ABT) posts promising Q4 results on strong growth in all lines and expansion in emerging markets.

                          Accuray (ARAY) Q2 Loss Narrower Than Estimates, Revenues Top

                          Radixact System and major software overhaul drive Accuray (ARAY) in Q2.

                            AngioDynamics (ANGO) Banks on Buyouts, Debt Level High

                            AngioDynamics (ANGO) continues to expand its business on the back of acquisitions and strategic alliances.

                              Walgreens Boots' Retail Pharmacy Strong, Competition Rife

                              Walgreens Boots (WBA) rides high on continued prescription growth and strength in the Retail Pharmacy USA division.

                                PetMed (PETS) Q3 Earnings Top Estimates, Reorder Sales Solid

                                The upside in third-quarter fiscal 2018 sales at PetMed (PETS) is a result of the significant increase in new orders and reorder sales.

                                  ResMed (RMD) Beats Q2 Earnings & Sales on Growth in All Lines

                                  ResMed (RMD) beats earnings and sales in Q2 on solid contributions from domestic and international businesses.

                                    Medtronic's FDA Nod for Riptide Aspiration System Boosts RTG

                                    Medtronic (MDT) makes efforts to boost RTG business.

                                      Medtronic (MDT) Wins FDA Nod for New Clinician Programmer

                                      Medtronic's (MDT) latest FDA nod likely to boost Pain Therapies division.

                                        5 Reasons Why You Should Offload Wright Medical Stock Now

                                        Foreign currency fluctuations and pricing pressure continue to be major headwinds for Wright Medical Group (WMGI).

                                          Medtronic's ITB Therapy Superior to CMM for PSS Reduction

                                          Medtronic (MDT) consistently tries efforts to boost Pain Therapies division, part of the Restorative Therapies Group.

                                            Myriad Genetics Fortifies Molecular Diagnostics With FDA Nod

                                            Myriad Genetics (MYGN) has been leaving no stone unturned to boost the uptake of BRACAnalysis CDx test and strengthen the Molecular Diagnostics portfolio.

                                              QIAGEN Partners DiaSorin, Boosts Molecular Diagnostics Arm

                                              QIAGEN (QGEN) continues to adopt initiatives to strengthen Molecular Diagnostics business.

                                                Illumina (ILMN) Ties Up With Thermo Fisher for Ion AmpliSeq

                                                Illumina (ILMN) consistently tries to enhance NGS platform.

                                                  Express Scripts 90-Day Analysis of Opioid Management Positive

                                                  Express Scripts (ESRX) addresses the national opioid epidemic by reducing excessive and improper opioid use.